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Abstract
Introduction: Two major gout-causing genes have been identified, the urate transport genes SLC2A9 and ABCG2.
Variation within the SLC17A1 locus, which encodes sodium-dependent phosphate transporter 1, a renal transporter
of uric acid, has also been associated with serum urate concentration. However, evidence for association with gout
is equivocal. We investigated the association of the SLC17A1 locus with gout in New Zealand sample sets.
Methods: Five variants (rs1165196, rs1183201, rs9358890, rs3799344, rs12664474) were genotyped across a New
Zealand sample set totaling 971 cases and 1,742 controls. Cases were ascertained according to American
Rheumatism Association criteria. Two population groups were studied: Caucasian and Polynesian.
Results: At rs1183201 (SLC17A1), evidence for association with gout was observed in both the Caucasian (odds
ratio (OR) = 0.67, P = 3.0 × 10-6) and Polynesian (OR = 0.74, P = 3.0 × 10-3) groups. Meta-analysis confirmed
association of rs1183201 with gout at a genome-wide level of significance (OR = 0.70, P = 3.0 × 10-8). Haplotype
analysis suggested the presence of a common protective haplotype.
Conclusion: We confirm the SLC17A1 locus as the third associated with gout at a genome-wide level of
significance.
Introduction
Regulation of serum urate concentration is central to the
development of gout, with renal uric acid excretion a criti-
cal checkpoint [1]. Genome-wide association scans exam-
ining the genetic control of serum urate concentrations
have identified two renal urate transporters - SLC2A9 and
ABCG2 - that have a strong effect on gout risk in multiple
ethnic groups [2]. Whilst other loci (SLC22A11, GCKR,
INHBC, SLC17A1, RREB1, PDZK1, SLC16A9, LRRC16A)
have been associated with serum urate concentrations at a
genome-wide level of significance in genome-wide associa-
tion scans [3,4], only some of them (SLC22A11, GCKR,
INHBC, SLC17A1) were associated with gout at a nominal
level of significance (P < 0.05) in 1,100 cases nested within
a large genome-wide association scan population-based
cohort [4]. To understand why some loci do not associate
with gout, and to assess the weakly associated loci in clini-
cal gout, it will be necessary to minimize heterogeneity
owing to the type of gout (primary or secondary to other
causes such as diuretic use) and to test for association in
clinically proven cases.
The solute carrier family 17 member 1 (encoded by
SLC17A1), also known as sodium phosphate transport
protein 1 (NPT1), is expressed on the apical membrane of
renal tubular cells and mediates sodium and inorganic
phosphate co-transport [5]. Sodium-dependent transporter
1 has also been identified as a urate transport protein [6,7],
probably secretory [7] with the gout-protective allele of
I269T [8] leading to increased sodium-dependent trans-
porter 1 activity [6] and, presumably, increased secretion
of uric acid. Genome-wide association scans have shown
that genetic variants associate with serum urate concentra-
tion in a Caucasian sample [3,4]. SLC17A1 has been
associated with gout in a Japanese sample set (I269T
(rs1165196), odds ratio (OR) = 0.55, P = 0.005) [8] but
with conflicting results in Caucasian sample sets. Marker
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rs1165205 in SLC17A3 was first associated with gout
(OR = 0.85, P = 0.002) [9]. A later study incorporating the
same clinical material with additional cases and controls,
however, reported reduced combined evidence for associa-
tion with gout using a strongly correlated marker within
SLC17A1 (rs1165196, r2 = 0.96; OR = 0.89, P = 0.013) [4] -
in this study the markers most strongly associated with
serum urate were within SLC17A1 (rs1165196 and other
tightly correlated markers), suggesting that this gene was
more likely than SLC17A3 to harbor an etiological variant.
A separate study reported no evidence in Caucasian for
association with gout (rs1183201, r2 with rs1165196 =
0.87, OR = 0.97, P = 0.68) [10]. This equivocal evidence
for association with gout in a Caucasian population is
notable given the genome-wide evidence for association
with serum urate concentration [4]. Both studies had ade-
quate power to detect association of a moderate effect
size, but neither study used clinical criteria to define gout.
Here, we aimed to test the SLC17A1 locus for associa-
tion with gout, in multiple ancestral groups, using cases
defined as a diagnosis of gout by the 1977 American Col-
lege of Rheumatology (ARA) clinical criteria. The var-
iants tested were rs1183201, demonstrated to influence
serum urate concentration in Caucasian populations [3],
the maximally gout-associated SNP (rs1165196 (I269T))
in Japanese [8], and three other SNPs predicted to tag
major variation in Polynesian populations.
Materials and methods
Study participants
There were a total of four New Zealand (NZ) case-control
sample sets, one of Caucasian ancestry and three of differ-
ent Polynesian ancestries (see Supplemental Table S1 in
Additional file 1). The sample sets were Eastern Polynesian
(EP; NZ Māori and Cook Islands, 284 cases and 349 con-
trols), Western Polynesian (WP; Samoa, Tonga, Niue and
Tokelau, 251 cases and 144 controls), combined Eastern
and Western Polynesian (EP/WP; 15 cases and 21 con-
trols) and Caucasian (421 cases and 1,228 controls; of the
controls, 590 had been SNP typed genome wide [11,12]).
The EP samples were further subdivided into two groups
to remove effects of stratification, as described in more
detail below, based on the estimated proportion of EP
ancestry (EP/N, 236 cases and 192 controls; and EP/Z,
48 cases and 157 controls). All gout cases recruited had a
diagnosis of gout confirmed according to the ARA preli-
minary diagnostic criteria [13]. Controls self-reported as
having no history of gout. Recruitment of cases was
approved by the NZ Multi-Region Ethics Committee
(MEC/05/10/130), and recruitment of controls by the
Lower South Ethics Committee. All patients provided
written informed consent for the collection of samples and
subsequent analysis.
Analysis of genome-wide microsatellite data indicates a
difference in population structure between Samoa and NZ
Māori [14] - with a Māori sample set estimated to be
~85% Polynesian and ~15% Caucasian ancestry, and a
Samoan sample set estimated at ~70% Polynesian, ~15%
Asian and smaller components of Melanesian and Cauca-
sian ancestry [14]. Analysis of genome-wide SNP data by
principal component analysis also shows a difference in
the first component between Samoan and Cook Island
genomes [15]. Given data also showing heterogeneity in
association of ABCG2 with gout in EP and WP sample
sets [16], the analysis groups here were EP and WP. Peo-
ple of combined EP and WP ancestry were included as a
separate group.
Power
The individual sample sets were inadequately powered to
detect an effect size in gout equivalent to that reported
previously (OR = 1.12) [4], with the largest dataset (Cauca-
sian) estimated to have 29% power at a = 0.05. However,
at larger effect sizes the Caucasian sample set was better
powered (63% power at OR = 1.2, 90% power at OR = 1.3
and 99% power at OR = 1.4). The smaller individual Poly-
nesian sample sets had less power (for OR = 1.4: EP = 67%
and WP = 45% using a Han Chinese Beijing (CHB) esti-
mate of minor allele frequency = 0.18), although the com-
bined Polynesian sample set was adequately powered with
88% power at OR = 1.4.
SNP selection and determination of genotypes
Using CHB HapMap data as the most closely related and
available population to Polynesia, Haploview software
(Broad Institute, Cambridge, MA, USA) was used to define
four haplotype blocks using the Gabriel confidence inter-
val method covering SLC17A1 (defined by rs4712972
(25.772 Mb) to rs12192635 (25.881 Mb)). Variants tagging
major haplotypes were selected: rs9358890 in block 1,
rs3799344 in block 2, rs1183201 in block 3 (previously
associated with control of serum urate concentration) [3]
and rs12664474 in block 4. The haplotype blocks extended
into flanking genes (SLC17A4 and SLC17A3). In Centre
d’Etude du Polymorphisme Humain (CEU) Caucasian
population and the CHB population, rs1183201 and
rs3799344 exhibited some intermarker linkage disequili-
brium (LD) (r2 = 0.77 and 0.50, respectively) and
rs9358890 and rs12664474 also exhibited LD (r2 = 0.35
and 0.62, respectively). SNP rs9358890 is in SLC17A4, and
rs12664474 is in SLC17A3. SNP rs1165196 (SLC17A1) was
also selected, in strong LD with rs1183201 (r2 = 0.87 in
CEU and 0.91 in CHB) (Figure 1).
Genotyping was done by TaqMan® SNP genotyping
assays (Applied Biosystems, Foster City, CA, USA) using
a Lightcycler® 480 Real-Time PCR System (Roche,
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Indianapolis, IN, USA) for four SNPs: rs1183201 (assay
ID: C_1911034_10), rs9358890 (assay ID: C_25595118_
10), rs3799344 (assay ID: C_194536_10) and rs12664474
(assay ID: C_11189653_10). SNP rs1165196 was geno-
typed using Sequenom technology (Sequenom, Inc. San
Diego, CA, USA). SNPs rs9358890 and rs12664474 had
been genotyped over 590 of the Caucasian controls on
the Affymetrix 6 SNP array (Affymetrix, Santa Clara,
CA, USA) [12] - genotypes were imputed for rs3799344
and rs1183201with IMPUTE2, using HapMap3 CEU
(NCBI Build 36 (db126b)) as reference haplotypes.
Statistical analysis
ORs were calculated using PLINK software [17]. Because
the case-control sample sets were not matched for sex,
association analysis also included sex as a possible con-
founder. Analysis of association of haplotypes was also
performed using PLINK. Meta-analysis was carried out
using Rmeta software (within STATA 8.0, Stata, College
Station, TX, USA) to calculate the combined Mantel-
Haenszel OR using a fixed-effects model and the Breslow-
Day test for heterogeneity.
The Māori population of NZ is admixed, primarily Cau-
casian. This leads to genetic stratification, which is a con-
founding factor for case-control genetic studies, especially
when the prevalence of disease differs between the inter-
breeding populations. The prevalence of gout in NZ
Māori is approximately double that in NZ Caucasian [18].
Given this, it is not surprising that the EP case sample set,
which is predominantly NZ Māori (78% of cases, 93% of
controls), has a significantly greater proportion of self-
reported EP grandparents than does the control sample
set (average of 3.1 EP grandparents in cases vs. 2.5 in con-
trols, P = 3.1 × 10-14 by t test). Sixty-seven biallelic geno-
mic control markers (see Supplemental Table 2 in
Additional file 1) were genotyped in the EP sample set,
and STRUCTURE software [19] was used to estimate the
individual proportion of EP ancestry. This estimation was
performed using the following parameters: number of
populations assumed to be two, 30,000 burn-in period,
and 100,000 Markov chain Monte Carlo replications after
burn-in. Caucasian control individuals genotyped for the
67 markers were included as representative of the ances-
tral Caucasian population to aid in population clustering,
although we were unable to include EP ancestral represen-
tatives. Plots of self-reported ancestry versus STRUCTURE
estimated ancestry are shown in Supplemental Figure 1 in
Additional file 1. For association analysis we created two
datasets matched for EP ancestry - EP/N with estimated
EP ancestry > 0.65 (the geometric mean; 236 cases and
192 controls), and EP/Z with estimated EP ancestry ≤ 0.65
(48 cases and 157 controls). The estimated average pro-
portion of EP ancestry in the EP/N sample set was 0.90 in
cases and 0.88 in controls, and for the EP/Z group was
0.41 in cases and 0.40 in controls.
Results
Association with gout was observed in the NZ Cauca-
sian sample set for rs1165196, rs1183201, rs3799344
and rs12664474 (OR = 0.71 (95% confidence interval
   SLC17A4     SLC17A1                      SLC17A3             SLC17A4     SLC17A1                      SLC17A3       
Figure 1 Intermarker linkage disequilibrium for Caucasian and Chinese populations. Intermarker linkage disequilibrium r2 values for
Caucasian (Centre d’Etude du Polymorphisme Humain; left) and Chinese (Han Chinese Beijing; right) populations. Approximate gene positions
are shown. Diagram generated with Haploview using data from www.hapmap.org.
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(CI) = 0.60 to 0.83), P = 5.5 × 10-5; OR = 0.67 (95% CI
= 0.57 to 0.79), P = 3.0 × 10-6; OR = 0.69 (95% CI =
0.58 to 0.81), P = 2.8 × 10-5; and OR = 1.36 (95% CI =
1.12 to 1.66), P = 1.3 × 10-3, respectively), but not for
rs9358890 (OR = 1.31 (95% CI = 0.93 to 1.85), P =
0.17) (Table 1). Given the low LD between rs12664474
and rs1183201 in CEU (r2 = 0.16), suggesting the possi-
bility of an independent effect at rs12664474, we tested
for association of rs12664474 conditional on genotype
at rs1183201 in the NZ Caucasian samples; there was
no evidence for a separate genetic effect on gout risk at
rs12664474 (P = 0.37). We also tested for conditional
associations at rs1183201 and rs1165196 (r2 in controls =
0.90) - there was association at rs1183201 conditional on
genotype at rs1165196 (P = 0.007), but not at rs1165196
when conditioned on genotype at rs1183201 (P = 0.14).
The five variants were then tested for association in the
Polynesian sample sets (Table 1), with the only evidence
for association in individual sample sets coming from
WP at rs1183201 (OR = 0.70, P = 0.03) and rs3799344
(OR = 0.67, P = 0.02). However, meta-analysis of the
Polynesian sample sets - carried out to increase power -
replicated the association observed in Caucasian at
rs1165196 (OR = 0.75 (95% CI = 0.60 to 0.94), P = 0.013,
PHet = 0.33), rs1183201 (OR = 0.74 (95% CI = 0.61 to
0.91), P = 0.003, PHet = 0.57) and rs3799344 (OR = 0.74
(95% CI = 0.61 to 0.90), P = 0.003, PHet = 0.33), but not
at rs9358890 (OR = 1.15 (95% CI = 0.95 to 1.40), P =
0.16, PHet = 0.28) or rs12664474 (OR = 1.16 (95% CI =
0.96 to 1.40), P = 0.13, PHet = 0.23).
The Caucasian and Polynesian sample sets were com-
bined in meta-analysis for rs1165196 (OR = 0.72 (95%
CI = 0.64 to 0.82), P = 5.7 × 10-7), rs1183201 (OR = 0.70
(95% CI = 0.62 to 0.79), P = 3.0 × 10-8, PHet = 0.64),
rs9358890 (OR = 1.19 (95% CI = 1.00 to 1.41), P = 0.05,
PHet = 0.37), rs3799344 (OR = 0.71 (95% CI = 0.62 to
0.80), P = 7.4 × 10-8, PHet = 0.43), and rs12664474 (OR =
1.25 (95% CI = 1.09 to 1.43), P = 2.0 × 10-3, PHet = 0.23).
Of the five SNPs, rs1183201 was the only one significant
at a genome-wide level of significance (P < 5 × 10-8). None
of the SNPs were significantly associated with serum urate
in either the Caucasian controls (for whom there were
serum urate data available; see Supplemental Table 1 in
Additional file 1) or the less admixed combined WP and
EP/N controls (all P > 0.28).
Because haplotypes are multi-allelic we analyzed associa-
tion of haplotypes with gout, with the purpose of investi-
gating the mechanism of effect - that is, whether risk and/
or protective variants are present and comparing associa-
tion pattern between populations. Analysis of four-marker
haplotypes (rs9358890-rs3799344-rs1183201-rs12664474;
Table 2) revealed the most consistent evidence for associa-
tion to come from the A-T-A-A haplotype (OR = 0.30 to
0.84), with significant association in the Caucasian, WP
and EP/WP sample sets (P = 1.5 × 10-6 to 0.035).
Discussion
Genetic regulators of serum urate concentration that
have been previously associated with gout at a genome-
wide level of significance (P < 5 × 10-8) in Caucasian
samples are SLC2A9 [4,9,20] and ABCG2 [4,9,16]. Here,
we provide strong evidence for a role of the SLC17A1
locus in gout in a Caucasian population (rs1183201,
OR = 0.67, P = 3.0 × 10-6; Table 1) that was replicated in
Polynesian samples, with the minor allele of rs1183201
also conferring a similar degree of risk (OR = 0.74, Pmeta-
analysis = 3.0 × 10
-3). The haplotype data (Table 2) are
consistent with the presence of at least one genetic var-
iant influencing the risk of gout at the SLC17A1 locus.
We hypothesize that the variant is protective of gout and
is contained on a common haplotype (27 to 43%; A-T-A-
A), conferring significant protection in three out of the
five sample sets (also with OR < 1 in both EP sample
sets). There were no haplotypes consistently conferring
risk. Combining the populations provided a genome-wide
level of significance for association of rs1183201 with
gout (OR = 0.70, P = 3.0 × 10-8). This confirms the
SLC17A1 locus as the third associated with gout.
The role of SLC17A1 has been previously evaluated in
gout in a Japanese sample set [8], with the nonsynon-
ymous variant I269T (rs1165196) having the strongest
evidence for association (OR = 0.55, P = 0.004, minor
allele (269T) protective). rs1165196 is in strong LD with
rs1183201 -the maximally associated variant in our
study - in Japanese (HapMap JPT) and Caucasian (Hap-
Map CEU) samples (r2 = 0.92 and r2 = 0.87, respec-
tively). Given that I269T has been shown to affect the
function of SLC17A1, with the protective variant (269T,
minor allele of rs1165196) leading to increased activity
in Xenopus oocytes and, presumably, increased renal
elimination of urate [6], it is therefore possible that
rs1165196 is an etiological variant. However, we found
no evidence in the Caucasian sample set supporting
association at rs1165196 when conditioned on genotype
at rs1183201, and association was weaker at rs1165196
than rs1183201 in combined Caucasian and Polynesian
meta-analysis (OR = 0.72, P = 5.7 × 10-7 and OR = 0.70,
P = 3 × 10-8, respectively) and in Polynesian alone (OR
= 0.75, P = 0.013 and OR = 0.74, P = 0.003, respectively)
(we did not conditionally analyze the small Polynesian
sample sets). Ostensibly this observation argues that
rs1183201 (or a variant in strong LD) is more likely
than rs1165196 to be an etiological variant within
SLC17A1. Given that rs1165196 has a stronger effect in
serum urate levels in Caucasian ([4] b = 6.205 vs. 6.050
for rs1183201) populations, however, this interpretation
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Table 1 Association analysis in New Zealand case-control sample sets
SNPa Cases MAF Controls MAF Punadjusted Padjusted
b OR (95% CI) HWE case HWE control
rs1165196 TT CT CC C TT CT CC C
Caucasian 167 (0.400) 201 (0.482) 49 (0.118) 0.359 389 (0.318) 590 (0.482) 246 (0.200) 0.442 1.0 × 10-4 5.5 × 10-5 0.71 (0.60 to 0.83) 0.33 0.41
EP/N 130 (0.570) 86 (0.377) 12 (0.053) 0.241 98 (0.516) 77 (0.405) 15 (0.079) 0.282 0.19 0.26 0.81 (0.60 to 1.11) 0.65 0.98
EP/Z 16 (0.364) 22 (0.500) 6 (0.136) 0.386 53 (0.358) 64 (0.432) 31 (0.209) 0.426 0.51 0.88 0.85 (0.52 to 1.38) 0.72 0.16
WP 138 (0.556) 99 (0.399) 11 (0.044) 0.244 69 (0.496) 54 (0.388) 16 (0.115) 0.309 0.05 0.06 0.72 (0.52 to 1.00) 0.20 0.28
EP/WP 10 (0.667) 5 (0.333) 0 (0.000) 0.167 6 (0.316) 10 (0.526) 3 (0.158) 0.421 0.02 0.07 0.28 (0.09 to 0.87) 0.33 0.73
Combinedc 5.7 × 10-7 0.72 (0.64 to 0.82)
rs1183201d TT TA AA A TT TA AA A
Caucasian 158 (0.384) 205 (0.499) 48 (0.117) 0.366 356 (0.291) 608 (0.496) 261 (0.213) 0.461 2.0 × 10-6 3.0 × 10-6 0.67 (0.57 to 0.79) 0.13 0.89
EP/N 130 (0.570) 86 (0.377) 12 (0.053) 0.241 96 (0.505) 78 (0.411) 16 (0.084) 0.289 0.11 0.14 0.78 (0.57 to 1.06) 0.65 0.98
EP/Z 15 (0.349) 21 (0.488) 7 (0.163) 0.407 52 (0.349) 61 (0.409) 36 (0.242) 0.446 0.49 0.95 0.85 (0.52 to 1.39) 0.94 0.04
WP 132 (0.543) 101 (0.416) 10 (0.041) 0.249 68 (0.479) 57 (0.401) 17 (0.120) 0.320 0.03 0.03 0.70 (0.51 to 0.97) 0.08 0.35
EP/WP 9 (0.600) 6 (0.400) 0 (0.000) 0.200 7 (0.350) 10 (0.500) 3 (0.150) 0.400 0.07 0.11 0.38 (0.13 to 1.12) 0.25 0.99
Combinedc 3.0 × 10-8 0.70 (0.62 to 0.79)
rs9358890 AA AG GG G AA AG GG G
Caucasian 366 (0.884) 47 (0.114) 1 (0.002) 0.059 1114 (0.912) 104 (0.085) 4 (0.003) 0.046 0.12 0.17 1.31 (0.93 to 1.85) 0.69 0.35
EP/N 97 (0.418) 99 (0.427) 36 (0.155) 0.369 80 (0.419) 78 (0.408) 33 (0.173) 0.377 0.80 0.71 0.96 (0.73 to 1.28) 0.21 0.07
EP/Z 34 (0.753) 11 (0.244) 0 (0.000) 0.122 129 (0.827) 26 (0.167) 1 (0.006) 0.090 0.44 0.42 1.41 (0.67 to 2.96) 0.35 0.80
WP 110 (0.440) 101 (0.404) 39 (0.156) 0.358 73 (0.507) 61 (0.424) 10 (0.069) 0.281 0.03 0.06 1.43 (1.04 to 1.95) 0.06 0.57
EP/WP 8 (0.533) 7 (0.467) 0 (0.000) 0.233 12 (0.571) 7 (0.333) 2 (0.095) 0.262 0.78 0.87 0.86 (0.29 to 2.55) 0.24 0.53
Combinedc 0.05 1.19 (1.00 to 1.41)
rs3799344 CC CT TT T CC CT TT T
Caucasian 165 (0.404) 193 (0.473) 50 (0.123) 0.359 379 (0.309) 592 (0.483) 255 (0.207) 0.450 5.9 × 10-6 2.8 × 10-5 0.69 (0.58 to 0.81) 0.58 0.38
EP/N 128 (0.561) 88 (0.386) 12 (0.053) 0.246 97 (0.524) 73 (0.395) 15 (0.081) 0.278 0.46 0.37 0.84 (0.62 to 1.15) 0.53 0.80
EP/Z 17 (0.378) 22 (0.489) 6 (0.133) 0.378 53 (0.353) 64 (0.427) 33 (0.220) 0.433 0.35 0.72 0.79 (0.49 to 1.29) 0.79 0.49
WP 136 (0.551) 98 (0.397) 13 (0.053) 0.251 64 (0.457) 59 (0.421) 17 (0.121) 0.332 0.02 0.02 0.67 (0.49 to 0.93) 0.39 0.55
EP/WP 10 (0.667) 5 (0.333) 0 (0.000) 0.167 7 (0.350) 10 (0.500) 3 (0.150) 0.400 0.04 0.08 0.30 (0.10 to 0.95) 0.44 0.85
Combinedc 7.4 × 10-8 0.71 (0.62 to 0.80)
rs12664474 AA AG GG G AA AG GG G
Caucasian 264 (0.632) 134 (0.321) 20 (0.048) 0.208 867 (0.707) 321 (0.262) 38 (0.031) 0.162 0.01 1.2 × 10-3 1.36 (1.12 to 1.66) 0.57 0.22
EP/N 90 (0.383) 104 (0.443) 41 (0.174) 0.396 74 (0.392) 77 (0.407) 38 (0.201) 0.405 0.79 0.17 0.96 (0.73 to 1.27) 0.25 0.03
EP/Z 25 (0.543) 18 (0.391) 3 (0.065) 0.261 107 (0.704) 39 (0.257) 6 (0.039) 0.168 0.05 0.13 1.75 (1.00 to 3.05) 0.92 0.32
WP 102 (0.411) 106 (0.427) 40 (0.161) 0.375 63 (0.444) 67 (0.472) 12 (0.085) 0.320 0.13 0.10 1.27 (0.93 to 1.73) 0.16 0.32
EP/WP 7 (0.467) 6 (0.400) 2 (0.133) 0.333 12 (0.571) 7 (0.333) 2 (0.095) 0.262 0.51 0.38 1.41 (0.51 to 3.92) 0.70 0.53
Combinedc 2.0 × 10-3 1.25 (1.09 to 1.43)
CI, confidence interval; HWE, MAF, OR, odds ratio. aGenotyping success rate: rs1165196 Caucasian, Eastern Polynesian (EP), Western Polynesian (WP) and EP/WP - cases 99.0%, 95.8%, 98.8% and 100%, respectively,
controls 99.8%, 96.8%, 96.5% and 90.5%, respectively; rs1183201 Caucasian, EP, WP and EP/WP - cases 97.6%, 95.4%, 96.8% and 100%, respectively, controls 99.7%, 97.1%, 98.6% and 95.2%, respectively; rs9358890
Caucasian, EP, WP and EP/WP - cases 98.3%, 97.5%, 99.6% and 100%, respectively, controls 99.2%, 99.4%, 100% and 90.5%, respectively; rs3799344 Caucasian, EP, WP, EP/WP - cases 96.9%, 96.1%, 98.4% and 100%,
respectively, controls 99.8%, 96.0%, 97.2% and 95.2%, respectively; rs12664474 Caucasian, EP, WP, EP/WP - cases 99.3%, 98.9%, 98.8% and 100%, respectively, controls 99.8%, 97.7%, 98.6% and 100%, respectively.
bAdjusted for sex. cMeta-analysis by the Mantel-Haenszel method. Breslow-Day test for heterogeneity: rs1165196, P = 0.45; rs1183201, P = 0.75; rs9358890, P = 0.77; rs3799344, P = 0.58; rs12664474, P = 0.97.

















should await further testing in larger gout and serum
urate sample sets.
In the Caucasian analysis, rs1183201 was strongly
associated with gout (OR = 0.67 (95% CI = 0.57 to
0.79)). This SNP, or SNPs in strong LD, has been stu-
died for association with gout in two previous studies:
Yang and colleagues [4], with OR = 0.89 (95% CI = 0.82
to 0.98); and Stark and colleagues [10], with OR = 0.97
(95% CI = 0.86 to 1.11). The strength of effect in our
study is considerably greater than the previous studies,
with a 95% CI that does not overlap with either study.
Given that the control allele frequencies were similar
between our study and those of Yang and colleagues [4]
and Stark and colleagues [10] (0.461 (rs1183201), 0.46
(rs1165196), and 0.487 (rs1183201), respectively), the
differences in effect size are therefore caused by differ-
ences in allele frequency in case sample sets. Differences
in ascertainment of cases are a possible reason for this
effect. Here, cases were clinically ascertained by ARA
criteria with exclusion of patients suspected of having
diuretic-induced gout. In Yang and colleagues’ study,
cases were drawn from five population-based cohorts
and were ascertained by: self-report or allopurinol
treatment (AGES Reykjavik Study); self-report (Athero-
sclerosis Risk in Communities Study); receiving gout
medication (allopurinol, colchicine, probenecid; Cardio-
vascular Health Study); self-report (Framingham Heart
Study); and receiving gout medication (allopurinol, col-
chicine, probenecid, benzbromarone; Rotterdam Study)
[4]. In Stark and colleagues’ study, cases were ascer-
tained by self-report and review of medical history [10].
In the study by Yang and colleagues no details were
included about the inclusion, or otherwise, of diuretic-
induced cases [4]; and in the study by Stark and collea-
gues 36.1% of cases were taking diuretic medication
[10]. The use of self-reported gout probably results in
participants without clinical evidence for gout being
included in case sample sets; for example, only 69% of
men who self-reported as new cases of gout met the
ARA classification criteria for gout [21], and reliability
and sensitivity for self-reported gout have been esti-
mated at 63 to 73% and 84%, respectively [22]. Although
the reliability of use of medications such as allopurinol,
colchicine, probenecid and benzbromarone has not been
extensively investigated for gout classification, the use of
allopurinol prescription gives a positive predictive value
of 39% for probable/definite gout [23]. Certainly, gout
case sample sets ascertained using such indirect criteria
had lower effect sizes reported at SLC2A9, compared
with sets using ARA criteria [20]. The method of ascer-
tainment in the previous studies [4,10] would thus
reduce power to detect association at SLC17A1 owing to
inclusion of nongout participants in the case sample
sets. The use of diuretic medications is well established
as a gout risk factor [24], perhaps by inhibition of urate
excretion mediated by human organic anion transporter
4 [25]. In Stark and colleagues’ study [10], this could
reduce power to detect association by studying cases
with secondary gout, since the inhibitory effect of diure-
tic medication on organic anion transporter 4-mediated
renal urate excretion would predominate over the
genetic effect on gout risk mediated by the SLC17A1
locus. It is also conceivable that diuretics directly influ-
ence the function of urate transporters encoded in the
locus. The loop diuretic bumetanide has recently been
shown to be a transport substrate for sodium-dependent
transporter 4 (encoded by SLC17A3), and functional
polymorphic variants are likely to influence transport
ability [26]. Given the likelihood that gene-diuretic
interactions exist, one would be prudent to exclude gout
cases taking diuretic medication as a potential con-
founding factor in order to evaluate the direct effect of
genetic variation in the SLC17A1 locus on primary gout.
Conclusion
We provide, for the first time, a genome-wide level of
evidence supporting a role for genetic variation in the
Table 2 Association of four-marker rs9358890-rs3799344-
rs1183201-rs12664474 haplotypes with gout
Frequency
Haplotypea Case Control OR (95% CI) P value
Caucasian
A-T-A-A 270 (0.339) 1044 (0.428) 0.66 (0.56 to 0.78) 1.5 × 10-6
A-C-T-A 327 (0.410) 876 (0.360) 1.22 (1.03 to 1.44) 0.014
A-C-T-G 121 (0.152) 284 (0.117) 1.34 (1.06 to 1.69) 0.015
G-C-T-G 47 (0.059) 104 (0.043) 1.39 (0.98 to 1.98) 0.067
EP/N
A-T-A-A 107 (0.239) 101 (0.274) 0.84 (0.61 to 1.15) 0.27
A-C-T-A 160 (0.356) 109 (0.297) 1.33 (0.99 to 1.78) 0.06
G-C-T-G 161 (0.360) 140 (0.380) 0.93 (0.70 to 1.23) 0.60
EP/Z
A-T-A-A 32 (0.372) 120 (0.414) 0.84 (0.51 to 1.38) 0.49
A-C-T-A 32 (0.372) 111 (0.384) 0.95 (0.58 to 1.56) 0.84
G-C-T-G 9 (0.105) 26 (0.090) 1.19 (0.53 to 2.64) 0.68
A-C-T-G 10 (0.116) 22 (0.075) 1.63 (0.74 to 3.59) 0.23
WP
A-C-T-A 171 (0.357) 96 (0.343) 1.07 (0.78 to 1.45) 0.70
A-T-A-A 116 (0.241) 89 (0.318) 0.68 (0.49 to 0.94) 0.021
G-C-T-G 171 (0.356) 77 (0.275) 1.46 (1.06 to 2.02) 0.021
A-C-T-G 12 (0.025) 12 (0.043) 0.57 (0.25 to 1.29) 0.17
EP/WP
A-T-A-A 5 (0.167) 16 (0.400) 0.30 (0.10 to 0.95) 0.035
A-C-T-A 15 (0.500) 13 (0.324) 2.08 (0.78 to 5.50) 0.14
G-C-T-G 6 (0.200) 11 (0.275) 0.66 (0.21 to 2.05) 0.47
CI, confidence interval; EP, Eastern Polynesian; OR, odds ratio; WP, Western
Polynesian. aHaplotypes are listed in descending order of control frequency;
those with frequency < 0.03 were excluded.
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SLC17A1 locus in the etiology of gout. This is the third
urate transport locus associated with gout with this
robust level of evidence, and our results further empha-
size the importance of urate transport in gout.
Additional material
Additional file 1: Supplemental Table 1 presenting participant
demographic and clinical details, Supplemental Table 2 presenting
genomic control SNPs, and Supplemental Figure 1 showing the
correlation of self-reported number of EP grandparents with
estimated EP ancestry using 67 genomic control markers.
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